CN1235605C - Medicinal composition for treating gall - Google Patents
Medicinal composition for treating gall Download PDFInfo
- Publication number
- CN1235605C CN1235605C CN 02158234 CN02158234A CN1235605C CN 1235605 C CN1235605 C CN 1235605C CN 02158234 CN02158234 CN 02158234 CN 02158234 A CN02158234 A CN 02158234A CN 1235605 C CN1235605 C CN 1235605C
- Authority
- CN
- China
- Prior art keywords
- present
- medicinal composition
- schefflerae arboricolae
- treating
- caulis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicinal composition for treating galls, particularly to the medicinal composition for treating galls, which uses vegetal Chinese herbal medicines as raw materials. The medicinal composition of the present invention comprises the following raw materials with the weight proportioning: 76 to 304g of scandent schefflera root, 20 to 80g of delivery ampelopsis root, and 10.4 to 41.6g of largeleaf Japanese ginseng rhizome. A toxicity test is carried out to prove that the medicinal composition of the present invention does not have poison and side effects; the present invention has obvious functions for resisting inflammation, alleviating pain, improving microcirculation, inhibiting hyperplasia of mammary glands, etc. through pharmacodynamics research; and the present invention is used clinically to prove that the total effective rate for treating diseases, such as traumatic injury, rheumatic arthritis, periarthritis humeroscapularis, gout, hyperplasia of lobuli glandulae mammariae, etc., can reach more than 90%.
Description
Technical field
The present invention relates to the pharmaceutical composition that a kind of treatment is swollen and ache, particularly relate to the pharmaceutical composition that a kind of treatment that with the vegetable Chinese herbal medicine is raw material is made is swollen and ache.
Background technology
Chinese patent CN1368369A (patent No. ZL011037105) discloses " a kind of treatment pain disease medicine ", it is characterized in that being made by following component: Cortex Eucommiae 12-16, eupolyphaga 3-6, Bombyx Batryticatus 4-5, Cortex Cinnamomi 10-15, hippocampus 3-5, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 8-11, Colla cornus cervi 8-12, Agkistrodon 2-4, Caulis Bauhiniae Championii 8-12, Typhonium flagelliforme (Lodd.) Blume 3-5, Pheretima 4-5, Hibisci Mutabilis root 10-12, Fructus Nandinae Domesticae 8-10, Cortex Mori dermatome 8-11, Radix Angelicae Sinensis 9-12, Rhizoma Drynariae 7-11, Radix Fructus Gardeniae 4-5, Scolopendra 1-2.Its preparation method is that said medicine is mixed with two parts by weight, will be wherein 1 part water logging 100-140 minute, the water yield is as the criterion there not to be medicine; Another part pulverized, and be stand-by behind at least 100 mesh sieves excessively; Be heated to boil after, slow fire boiling 50-80 minute, filter out that for the first time medicinal liquid is stand-by; The former medicinal residues of medicinal liquid of gaining life experience out add water again and did not have powder, be heated to boil after, slow fire boiling 50-80 minute, leach medicinal liquid; Merge medicinal liquid twice, the heated and boiled transpiring moisture makes it become paste; Above-mentioned another part joined in above-mentioned paste raw materials by the 1/10-3/10 medicated powder of identical weight through the former medicine weight of 100 mesh sieves at least, stir, drying is pulverized again, crosses 100 mesh sieves at least and is product of the present invention.
Chinese patent CN1313123A (patent No. ZL011065265) discloses " a kind of Sancao analgesic ", comprise Deng Fengcao, three kinds of medical herbs of Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) and little Herba Piper Spuberuli, its composition by weight is: step on phoenix grass 3-13, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 3-13, little Herba Piper Spuberuli 1-4, the medicated wine manufacture method is: Deng Fengcao, the collection of Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) and three kinds of medical herbs of little Herba Piper Spuberuli, clean respectively, airing or dry is cut into the long decoction pieces of 2-3 centimetre, steps on by every composition by weight and purchases careless 3-13 part, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 3-13 part, little Herba Piper Spuberuli 1-4 part weighs up, put into and soak cylinder, is 1 by former medicine than the proportional quantity of wine: 6-9 adds the above rice wine of 20 degree and soaked 7-15 days, leaches medicated wine, packages spare; Capsular manufacture method: the collection of stepping on wind grass, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) and three kinds of medical herbs of little Herba Piper Spuberuli, each is cleaned, airing or dry, step on by every composition by weight and to purchase careless 3-13 part, Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 3-13 part, little Herba Piper Spuberuli 1-4 part and weigh up, put into saucepan, is 1 by former medicine than the proportional quantity of water: 4-7 adds shallow water, and the former is also surplus about half to medicinal liquid, pick up medicinal residues, filtration, continue to decoct liquid and when being condensed into cream drug, stop inflammation, taking out cream drug is put in and dries in the dish or into oven for drying, levigation incapsulates eastern finished product.
Summary of the invention
Purpose of the present invention is intended to provide a kind of traumatic injury, rheumatism combination of oral medication evident in efficacy, safe in utilization for the treatment of.
The pharmaceutical composition that treatment of the present invention is swollen and ache is the medicament of being made by the following weight proportion raw material:
Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 76-304 Delavay ampelopsis root 20-80 Rhizoma Panacis Majoris 10.4-41.6
In above-mentioned composition, also can contain the Radix Glycyrrhizae 4-16 of weight proportion, Fructus Gardeniae 20-80.Fructus Gardeniae wherein can substitute with Radix Salviae Miltiorrhizae.
The present invention is principal agent with the Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae), and the sweet temperature of Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) is arrogated to oneself alleviating pain and detumescence, relaxing muscles and tendons and activating QI and blood in the collateral, and expelling wind and removing dampness is used for various rheumatalgias, traumatic injury and traumatic hemorrhage; Delavay ampelopsis root is arduous warm in nature, expelling wind and removing dampness, and dispelling cold by warming the meridian, blood-activating analgetic is kindly controlled pain of a specified duration and is gone into network, be total to control wind and control blood earlier oneself effect of going out of blood sector-style; Fructus Gardeniae, it is cold, heat-clearing and toxic substances removing, cooling blood and relieving pain, dispersing swelling and dissipating binds are arrogated to oneself the disease of separating red, swollen, hot, the pain due to the pyretic toxicity stasis of blood resistance meridians; This strengthens principal agent Repercusion analgesia, blood circulation invigorating efficacies and is ministerial drug.Rhizoma Panacis Majoris fills blood and relaxing muscles and tendons and activating QI and blood in the collateral, arrogates to oneself dispelling the wind and dampness pathogens pain, traumatic injury, strengthening vital QI to eliminate pathogenic factors and be adjuvant drug.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription has invigorating the spleen and replenishing QI concurrently, heat-clearing and toxic substances removing, the merit of relieving spasm to stop pain and be messenger drug.
Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) of the present invention is the dry Herb of Araliaceae Schefflera venulosa (Wight et Arn.) Harms Schefflera venulosa Wightet Arn., is stated from " Yunnan Province's drug standard " 1996:3; Delavay ampelopsis root is the dry root of beautiful Fructus Vitis viniferae Ampelopsis delavayana (Franch) Planch of vitaceae, is stated from " 1977:127 of Chinese pharmacopoeia and " Yunnan Province's drug standard " 1996:36; Rhizoma Panacis Majoris is the dry rhizome of Araliaceae Rhizoma Panacis Majoris Panax japonicus C.A.Mey.var.major (Burk) C.Y.Wu et K.M.Feng or Rhizoma Panacis bipinnatifidi Panax japonicus C.A.Mey.var.bipinnatifidus (Seem.) C.Y.Wu etK.M.Feng, is stated from " 2000:79 of Chinese pharmacopoeia; Radix Glycyrrhizae is the dry root and rhizome of glycyrrhizic legume Glycyrrhizauralensis Fisch. Glycyrrhiza inflata Bat. Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L. Glycyrrhizaglabra L., is stated from " 2000:65 of Chinese pharmacopoeia; Fructus Gardeniae is the dry mature fruit of Maguireothamnus speciosus Fructus Gardeniae Gardenia jasminoides Ellis, is stated from " 2000:201 of Chinese pharmacopoeia.
Medicament of the present invention is a said peroral dosage form on the pharmaceutics.Can be the capsule made through conventional technology of raw material of the present invention and corresponding medicinal adjuvant, tablet etc.
Pharmaceutical composition of the present invention has no side effect through the toxicity test proof; The effect that has significant antiinflammatory, analgesia and inhibition cyclomastopathy through pharmacodynamic study:, treatment of diseases total effective rates such as traumatic injury, rheumatic arthritis, scapulohumeral periarthritis, gout and cyclomastopathy are reached more than 90% through clinical trial.Be specially:
Toxicological study:
1. acute toxicity test
Toxicity prerun shows that the oral recovering capsule of hindering of mice is difficult to measure LD50, and mice is once irritated stomach with the dosage of 16g/kg does not have the overt toxicity reaction to hindering recovering capsule.The mice once maximum tolerated dose of oral said preparation is 16g/kg (amounting to crude drug amount 40.53g/kg), and this dosage calculates by kg body weight, is equivalent to 222 times of maximum consumption in the clinical people one day; Calculate by the relative ratio of body weight surface area, be equivalent to 18 times of the highest consumption of people one day.
2. long term toxicity test
The pain relieving capsule gives rat with 1g/kg. day, 2g/kg. day and 4g/kg. day continuous irrigation stomach 90 days, does not see that outward appearance appears in animal, body weight increases, and the toxicity of hemogram, blood biochemical and 13 kinds of organs and tissues changes.
Pharmacodynamic study
1, antiinflammatory test
(1) influence of rat assist agent arthritis
The primary affection that can obviously suppress rat assist agent arthritis, the offside foot swelling in the time of suppressing secondary affection again, and the General Symptoms when alleviating delayed hypersensitivity.
(2) influence of rat Ovum Gallus domesticus album foot swelling
Rat paw edema due to the Ovum Gallus domesticus album there is remarkable inhibitory action.
(3) xylol causes the influence of mice auricle swelling
Xylol causes mice auricle swelling remarkable inhibitory action.
(4) to the granulomatous influence of mice filter paper
Can significantly suppress the granulomatous generation of mice filter paper.
2, analgesic activity research
Can significantly suppress the writhing response that acetic acid causes the pain mice.
3, rheology test
Can obviously improve the every hemorheology index under the rat acute blood stasis state due to the epinephrine.
4, microcirculation disturbance test: can obviously improve experimental microcirculation disturbance due to the little parathyrine of mice kidney.
5, delayed hypersensitivity: the mice delayed hypersensitivity is had remarkable inhibitory action
6, can obviously suppress the arthroncus of uric acid sodium induced mice gouty.
7, the increase of diethylstilbestrol induced mice breast, cyclomastopathy pathological changes there is obvious inhibitory action
Clinical research:
Observation adopts independent medication to test to the clinical efficacy of diseases such as traumatic injury (soft tissue injury), rheumatic arthritis, scapulohumeral periarthritis, gout and cyclomastopathy.
Traumatic injury group (soft tissue injury): cure rate 16.13%; Obvious effective rate 64.52%; Effective percentage 19.35%; Total effective rate 100%.
Rheumatic arthritis group: cure rate 3.23%; Obvious effective rate 58.06%; Effective percentage 25.81%; Total effective rate 87.10%.
Scapulohumeral periarthritis group: cure rate 23.33%; Obvious effective rate 36.67%; Effective percentage 33.33%; Inefficiency 6.67%; Total effective rate 93.33%.
Gout group: cure rate 3.23%; Obvious effective rate 51.61%; Effective percentage 35.49%; Inefficiency 9.67%; Total effective rate 90.33%.
Cyclomastopathy group: obvious effective rate 46.43%; Effective percentage 28.57%; Inefficiency 25%; Total effective rate 75.00%.
The specific embodiment
Embodiment 1:
Get Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 110, Delavay ampelopsis root 40, Rhizoma Panacis Majoris 15, Fructus Gardeniae 30 is ground into coarse powder with said medicine, decocts with water twice, and collecting decoction filters, and filtrate is condensed into cream, drying under reduced pressure, crushing screening, powder gets dry extract.
Embodiment 2:
Get Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 160, Delavay ampelopsis root 45, Rhizoma Panacis Majoris 24, Radix Glycyrrhizae 5, Fructus Gardeniae 50 is ground into coarse powder with said medicine, decocts with water twice, and collecting decoction filters, and filtrate is condensed into cream, drying under reduced pressure, crushing screening, powder gets dry extract.
Embodiment 3:
Get Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 260, Delavay ampelopsis root 60, Rhizoma Panacis Majoris 30, Radix Glycyrrhizae 12 is ground into coarse powder with said medicine, decocts with water twice, and collecting decoction filters, and filtrate is condensed into cream, drying under reduced pressure, crushing screening, powder gets dry extract.
Claims (3)
1, the pharmaceutical composition that swells and ache of a kind of treatment is characterized in that it being the medicament of being made by the following weight proportion raw material:
Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 76-304 Delavay ampelopsis root 20-80 Rhizoma Panacis Majoris 10.4-41.6.
2, the pharmaceutical composition that swells and ache of a kind of treatment is characterized in that it being the medicament of being made by the following weight proportion raw material:
Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 76-304 Delavay ampelopsis root 20-80 Rhizoma Panacis Majoris 10.4-41.6 Radix Glycyrrhizae 4-16.
3, the pharmaceutical composition that swells and ache of a kind of treatment is characterized in that it being the medicament of being made by the following weight proportion raw material:
Radix Schefflerae Arboricolae (Caulis et Folium Schefflerae Arboricolae) 76-304 Delavay ampelopsis root 20-80 Rhizoma Panacis Majoris 10.4-41.6 Fructus Gardeniae 20-80.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02158234 CN1235605C (en) | 2002-12-18 | 2002-12-18 | Medicinal composition for treating gall |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02158234 CN1235605C (en) | 2002-12-18 | 2002-12-18 | Medicinal composition for treating gall |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1507914A CN1507914A (en) | 2004-06-30 |
| CN1235605C true CN1235605C (en) | 2006-01-11 |
Family
ID=34236926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02158234 Expired - Lifetime CN1235605C (en) | 2002-12-18 | 2002-12-18 | Medicinal composition for treating gall |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1235605C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347477B (en) * | 2008-06-16 | 2010-12-01 | 云南省药物研究所 | Medicament composition for treating rheumatoid arthritis |
| CN105920218B (en) * | 2016-05-28 | 2018-06-26 | 杨本雷 | A kind of Yi nationality cures water plaster |
-
2002
- 2002-12-18 CN CN 02158234 patent/CN1235605C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1507914A (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100336533C (en) | Traditional Chinese medicinal prepn. for treating constipation of slow-remove type, and its prepn. method | |
| CN101066303A (en) | Medicine for treating cerebral thrombus, cerebral angiosclerosis, apoplexy and hemiplegia and its prepn | |
| CN1193775C (en) | Rheumatoid disease treating capsule | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN101229355B (en) | Rheumatism soup | |
| CN104666579A (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method of traditional Chinese medicine composition | |
| CN103239579B (en) | Chinese medicine composition for treating acute facioplegia and preparation method thereof | |
| CN1289114C (en) | Arthralgia pain treating bolus and its prepn | |
| CN101337019A (en) | Oral traditional Chinese medicine formulation for treating herpes zoster post herpetic neuralgia and preparation method thereof | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN1907401A (en) | Decoction preparation for treating chronic eczema and its preparation process | |
| CN1235605C (en) | Medicinal composition for treating gall | |
| CN1077896A (en) | Medicine for psoriasis and manufacture method | |
| CN101869671A (en) | Paste for waist, leg, shoulder and neck | |
| CN104587414A (en) | Traditional Chinese medicinal composition for treating headache | |
| CN101019926A (en) | Chinese medicine for treating cardiac and cerebral vascular diseases and its prepn process | |
| CN100402065C (en) | Capsule for treating gout and preparation process thereof | |
| CN1234388C (en) | External-use medicinal composition for treating gall | |
| CN1814125A (en) | Rehmannia-root preparation | |
| CN1270768C (en) | Medicine for treating cold disease | |
| CN101129654B (en) | Orally taken traditional Chinese medicine for treating cerebral hemorrhage sequela | |
| CN101095810B (en) | Decoction medicine for treating seborrhoeic dermatitis and method for preparing the same | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1311849C (en) | Medicinal composition for treating swelling paint | |
| KR20020023455A (en) | Concentrated extract comprising Kalopanacis cortex as main ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040630 Assignee: Yunnan Baiyao Group Co.,Ltd. Assignor: YUNNAN INSTITUTE OF MATERIA MEDICA Contract record no.: 2014530000101 Denomination of invention: Medicinal composition for treating gall Granted publication date: 20060111 License type: Common License Record date: 20140909 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060111 |
|
| CX01 | Expiry of patent term |